tisotumab vedotin + bevacizumab

Tisotumab vedotin + bevacizumab is a combination investigational cancer therapy composed of **tisotumab vedotin**, an antibody-drug conjugate targeting tissue factor, and **bevacizumab**, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). Tisotumab vedotin delivers a cytotoxic payload (monomethyl auristatin E) directly to tissue factor-expressing cancer cells, causing cell death, while bevacizumab inhibits angiogenesis by preventing VEGF-A from binding its receptors on endothelial cells. This combination is under clinical investigation primarily for recurrent or metastatic cervical cancer, with studies demonstrating a manageable safety profile and promising antitumor activity[1][5][7]. Tisotumab vedotin was developed by Genmab and Seagen; bevacizumab was developed by Genentech/Roche.